In 93 patients with hypertension uncontrolled by bendrofluazide 5 mg plus atenolol 100 mg daily, the effects of adding nifedipine (up to 60 mg/day, n = 31), prazosin (up to 20 mg/day, n = 31), or hydralazine (up to 200 mg/day, n = 31) were compared in a 6 month open random parallel group study. The three drugs did not differ significantly as regards antihypertensive effect, withdrawal rate, total number of side effects, or effect on serum biochemical variables. The pattern of side-effects differed. Headache, flushing and oedema were common with nifedipine, tiredness and drowsiness with prazosin, and headache with hydralazine. Nifedipine is an acceptable third-line antihypertensive drug which may have some advantage over hydralazine and prazosin.
Introduction
Thiazide diuretics and beta-blockers have a favourable benefit-risk ratio even in very mild hypertension,' and should still be regarded as the antihypertensive drugs ofchoice. However they fail to control the blood pressure in 10-30% of patients, even when used in combination, and in the stepped-care method of treatment a third drug is added. In one large study2 hydralazine and prazosin proved superior to methyldopa, minoxidil and labetalol as third-line drugs. Hydralazine caused fewer subjective side effects than prazosin and appeared to be the third-line drug of choice.2 However, it failed to normalize the blood pressure in 75% of those treated, and it has also emerged that the incidence of the lupus syndrome during long-term hydralazine treatment is unacceptably high, even when the daily dose is limited to 200 mg.3 There is a clear need for third-line drugs which are safer, better tolerated and more effective. The calcium antagonist nifedipine has proved an effective third-line drug in short-term placebo-controlled studies.4 '5 We have compared nifedipine, prazosin, and hydralazine as third-line drugs in patients with hypertension uncontrolled by bendrofluazide plus atenolol, in a 6 months randomized parallel group trial.
Methods

Patients
Ninety-three hypertensive patients (42 men, 51 women; mean age 56 years, range 21-69) consented to the study, which was approved by the hospital ethics committee. They had taken bendrofluazide 5 mg plus atenolol 100 mg daily, and no other antihypertensive drug, for at least 4 weeks, and had supine blood pressure > 140 mm Hg systolic or > 95 mm Hg diastolic at each of three visits during a 4-week run-in period. Compliance was judged satisfactory by tablet counts.
Study design
At the end of the 4-week run-in period patients were randomized by opening sealed envelopes to one of three parallel groups receiving nifedipine, prazosin or hydralazine, in addition to bendrofluazide plus atenolol which were continued at constant dosage. Randomization was stratified for sex.
Treatments
The nifedipine, prazosin and hydralazine preparations and dose increments are shown in Table I . Treatments were all prescribed 'open-label', to be taken twice daily at approximately 0800 h and 1800 h. The first dose of all treatments was taken on retiring at night. The dose was increased (Table 1) (Table II) .
Overall outcome is shown in Table III . Twentyseven (29%) patients discontinued their trial drug because of side-effects. One patient was withdrawn because of incidental illness and was excluded from analysis. The analyses of blood pressure, pulse rate and body weight relate to the remaining 65 patients. The three drugs did not differ significantly as regards changes in supine blood pressure at six months (Table IV) . The fall in supine mean arterial pressure (diastolic + 1/3 pulse pressure) with nifedipine was slightly larger than that for hydralazine (by 4.1 mm Hg, 95% confidence interval [CI] -2.6 to + 10.7 mm Hg), and prazosin (by 1.3 mm Hg 95% CI -4.6 to 7.1 mm Hg). Of all those randomized, target blood pressure (supine systolic < 140mmHg and diastolic < 95 mm Hg) was attained at 6 months in 52% with nifedipine, 45% with prazosin and 33% with hydralazine. Comparing measurements 13 hours after dosing to those 3 hours after dosing, blood pressure tended to rise on all three drugs. Supine mean arterial pressure rose by 7.0 mm Hg on nifedipine (n = 11), 3 .5mm Hg on prazosin (n = 10) and 4.7 mm Hg on hydralazine (n = 7).
The fall in standing systolic pressure at six months was less with hydralazine than with nifedipine (P <0.01) or prazosin (P <0.05) (Table IV) .
Weight increased significantly during prazosin treatment (+1.4kg) when compared to nifedipine (0.0 kg, P = 0.05) or hydralazine (-0.6 kg, P < 0.005) treatment (Table IV) .
Twenty-six per cent of patients stopped nifedipine, 23% stopped prazosin, and 40% stopped hydralazine because of side effects (Table V) , after an average of 11 weeks treatment (range 1-23 weeks). The drug was stopped by the patient rather than the doctor in threequarters of cases. The three drugs did not differ in the frequency or total number of side effects volunteered in response to a standard open question (Table V) . However the pattern of side effects did differ. Headache, flushing and oedema were common with nifedipine; tiredness and drowsiness with prazosin; and headache with hydralazine. The questionnaires added little information, but did confirm that drowsiness was persistent during prazosin treatment. Drowsiness worsened over 6 months in 32% of patients taking prazosin, 11% taking hydralazine, and 5% taking nifedipine. It improved in 9% of those taking prazosin, none taking hydralazine, and 23% taking nifedipine.
Biochemical variables (Table VI) did not differ significantly between the drugs. Nifedipine did not lower serum potassium (+0.15mmol/l, 95% CI -0.11 to + 0.40) or increase random blood glucose compared to prazosin and hydralazine. Tablet counts were in error by less than 10% at 89% of visits, 10-20% at 4% of visits, > 20% at 0.3% of visits, and were not returned at 6% of visits. The accuracy of tablet counts did not differ between the three treatments.
Discussion
Nifedipine, prazosin and hydralazine are all more effective than placebo as third-line drugs2'4'5 and 6 months of placebo treatment could not be justified when designing the present study. In this study design, blood pressure falls by 9/5mm Hg supine and 10/6 mm Hg standing during 6 months of placebo treatment2 and the changes of blood pressure shown in Table IV exaggerate the true drug responses by about this amount. Treatments had to be prescribed 'open label' because of the complexity of the regimens, and this presented particular problems when assessing side effects. To avoid bias we used a standard open question and recorded all responses with no subjective interpretation. The decision whether to continue or stop a drug in a patient with side effects is also open to investigator bias. In this study the patient had stopped or reduced treatment before returning to the clinic in 75% of instances, and there is unlikely to be any important bias.
The three drugs did not differ significantly as regards their antihypertensive effects, apart from the smaller effect of hydralazine on standing systolic pressure, an observation of doubtful importance. The 95% confidence intervals indicate that any important difference between the drugs would favour nifedipine, which might lower supine mean arterial pressure more than prazosin or hydralazine by 7 mm Hg or 11 mm Hg respectively. However this trend in favour of nifedipine would probably be lost towards the end of the dose interval, as the rise in blood pressure 13 hours after dosing was slightly larger for nifedipine than for prazosin or hydralazine. We conclude that there is unlikely to be any important difference between these drugs in antihypertensive efficacy, at least when they are taken twice daily in the doses and formulations we used.
Subjective side effects were common with all three drugs, and treatment had to be stopped in 29% of all patients. Treatment was stopped after an average of 11 weeks, an observation which underlines the inadequacy of the ubiquitous 4-6 week trials for assessing the tolerability of antihypertensive drugs. Patients will put up with a great deal when they know that the duration of treatment is limited. The three drugs did not differ significantly as regards withdrawal rate, or the frequency and total number of side effects. The pattern of side effects did differ, and one has to weigh flushing, headache and oedema with nifedipine, tiredness and drowsiness with prazosin, and headache with hydralazine. We believe that drowsiness during prazosin treatment, which was common and persisted during the 6 months of treatment, is the least acceptable of the side effects elicited.
Our findings support the view that the pedal oedema which occurs commonly during nifedipine treatment is not a consequence of generalized fluid retention, as there was a clear dissociation between weight gain and oedema. Nifedipine caused no weight gain, yet caused oedema in 29% of patients. In contrast, prazosin induced significant weight gain, but caused oedema in only 16% of patients.
It has been suggested that nifedipine aggravates thiazide-induced hypokalaemia4 and may cause glucose intolerance.9 Our results do not support these suggestions. The 95% confidence intervals for changes in serum potassium show that it does not worsen hypokalaemia to any important extent. Which of these drugs should be preferred as thirdline treatment? Hydralazine is unsuitable because of the high incidence of the lupus syndrome during more prolonged treatment,3 and the choice lies between nifedipine and prazosin. There is little to choose between these two drugs. However the outcome for nifedipine might have been better had we used the slow-release formulation which has become available since this study was initiated. Considering this, and the frequent and persistent drowsiness during prazosin treatment, we now prefer nifedipine. The whole concept of stepped-care treatment has been called into question recently. The suggestion is that substitution of drugs such as calcium antagonists or ACE inhibitors may be preferable to stepwise addition of drugs. This may be so, and the results of this study and a similar one published previously2 certainly highlight the limitations of the third-line drugs currently available. However these limitations were exposed only in large prospective studies of several months duration. Those who advocate substitution rather than stepped-care would be on stronger ground if they could cite similar studies showing that the outcome of such treatment is more satisfactory, or even as satisfactory, as that of stepped-care treatment.
